Senti Biosciences shareholders approve officer exculpation and reverse stock split authorization (range 1:5 to 1:30)

Senti Biosciences, Inc.

Stockholders approved an officer exculpation amendment limiting liability of certain officers as permitted by Delaware law; effective July 10, 2024.
Reverse stock split approved at ratio between 1:5 and 1:30, as determined by the Board; Board may abandon the split.
KPMG LLP ratified as independent auditor for fiscal year ending Dec 31, 2024 (30,547,655 votes for, 63,495 against).
Officer exculpation amendment and reverse split were Proposals 2 and 3; 68.97% of outstanding shares represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.